BTZ-043 Dose Evaluation in Combination and Selection (DECISION)

Michael Hoelscher

Status and phase: Enrolling; Phase 2

Conditions: Other Specified Pulmonary Tuberculosis; Tuberculosis, Pulmonary

Treatments: Drug: Bedaquiline; Drug: BTZ-043; Drug: Moxifloxacin; Drug: Delamanid

Study type: Interventional

Funder types: Other

Identifiers

NCT05926466

UNITE4TB-02 (Other Identifier)

LMU-IMPH-BTZ-043-04

Details and patient eligibility

About

This is a phase 2B, open label study, that will compare the safety and efficacy of three experimental regimens consisting of bedaquiline and delamanid in combination with different doses of BTZ-043, a novel antibiotic, in adult participants with newly diagnosed, drug-sensitive pulmonary tuberculosis. Participants will be assigned to receive either one of the three BTZ-043-containing regimens or a comparator regimen consisting of bedaquiline, delamanid and moxifloxacin. The objective is to find the optimal dose of BTZ-043 with the highest efficacy and safety to be used in subsequent studies.

Full description

This open label, phase 2B, randomized controlled study will evaluate three experimental arms containing different doses of BTZ-043 in combination with bedaquiline and delamanid, in adult subjects with newly diagnosed, drug-sensitive pulmonary tuberculosis, in comparison with bedaquiline, delamanid and moxifloxacin, administered over 16 weeks. A total of 90 adult (≥ 18 years of age) participants will be enrolled. In case of a high number of dropouts or non-evaluable participants, it may be necessary to recruit more participants into the study.

The participants will be randomly allocated to one of the three BTZ-containing experimental regimens or the moxifloxacin-containing comparator regimen:

Arm 1: bedaquiline, delamanid, BTZ-043 500 mg (BDT500) Arm 2: bedaquiline, delamanid, BTZ-043 1000 mg (BDT1000) Arm 3: bedaquiline, delamanid, BTZ-043 1500 mg (BDT1500) Arm 4: bedaquiline, delamanid, moxifloxacin (BDM) In all arms, bedaquiline will be dosed at 400 mg once daily for 2 weeks, followed by 100 mg once daily for 14 weeks and delamanid will be dosed at 300 mg once daily for 16 weeks. Moxifloxacin will be dosed at 400 mg once daily in the comparator arm. After completion of 16 weeks of treatment, all participants will receive 8 weeks of continuation therapy with Rifampicin and Isoniazid.

Enrollment: 90 estimated patients

Sex: All

Ages: 18 to 64 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Provide written, informed consent prior to all trial-related procedures, including HIV testing.

• Male or female, aged 18 up to (and including) 64 years.

• Body weight (in light clothing and with no shoes) within the range of 30 to 100kg and body mass index within the range of 15 to 40kg/m2.

• Newly diagnosed, previously untreated current episode of drug-susceptible pulmonary TB (presence of MTB complex with rapid molecular test result confirming susceptibility to rifampicin and isoniazid such as "GeneXpert" and/or "HAIN MTBDR plus").

• ≥ 1 sputum sample from concentrated spot sputum positive in GeneXpert MTB/RIF Ultra®, with semi-quantitative result at least "medium" or higher.

• FEMALE PARTICIPANTS: Inability to conceive AND/OR inability of partner(s) to father children OR consent to use effective methods of contraception when engaging in heterosexual intercourse, as defined below:

  a. Non-childbearing potential: i) Bilateral oophorectomy AND/OR hysterectomy OR bilateral tubal ligation more than 12 months ago, AND/OR has been postmenopausal with a history of no menses for at least 12 consecutive months as per medical history.

ii) Sexual partner(s) of female participant: vasectomy OR bilateral orchidectomy at least three months prior to screening as per medical history.

b. Effective contraception methods: i) Two methods, including methods used by patient's sexual partner(s). At least one must be a barrier method. Contraception must be practised for at least until 12 weeks after the last dose of BTZ-043.

• MALE PARTICIPANTS: Inability to father children AND/OR inability of partner(s) to conceive, OR consent to use effective methods of contraception when engaging in heterosexual intercourse, as defined below:

c. Non-childbearing potential: i) Sexual partner(s) of male participant: Bilateral oophorectomy AND/OR hysterectomy OR bilateral tubal ligation more than 12 months ago, AND/OR has been postmenopausal with a history of no menses for at least 12 consecutive months as per medical history.

ii) Vasectomy OR bilateral orchidectomy at least three months prior to screening as per medical history.

iii) Female pregnant sexual partner of a male participant: agree to use at least one barrier method.

iv) Male sexual partner of male participant: agree to use at least one barrier method for at least until 12 weeks after the last dose of BTZ-043 for protection of the partner.

d. Effective contraception methods: ii) Two methods, including methods used by patient's female sexual partner(s). At least one must be a barrier method. Effective contraception must be ensured for at least 16 weeks after the last dose of BTZ-043

Exclusion criteria

• Circumstances that raise doubt about free, unconstrained consent to study participation (e.g. in a prisoner or person suffering from an intellectual disability).

• Poor general condition, where delay in treatment cannot be tolerated, or death within three months is likely, as assessed by the investigator.

• Poor social condition which would result in a high likelihood of not completing the trial until the final visit.

• The patient is pregnant or breast-feeding.

• The patient is HIV antibody positive (known, or on a test performed at screening), unless:

  1. The patient has a viral load (VL) < 200 copies/mL on a test performed at screening
  2. The patient has a CD4 cell count > 200 cells/mm3 at screening
  3. The patient is experienced on antiretroviral therapy (ART), and is on a combination of tenofovir, lamivudine and dolutegravir (TDF/3TC/DTG) for a minimum of 6 months prior to the screening visit.

• The patient has a known intolerance to any of the study drugs or concomitant disorders or conditions for which study drugs or standard TB treatment are contraindicated.

• The patient has received treatment with any other investigational drug within 1 month prior to enrolment, or is planning to be enrolled into other clinical (intervention) trials during participation.

• The patient has a history of or current evidence of clinically relevant cardiovascular, metabolic, gastrointestinal, neurological, ophthalmological, psychiatric or endocrine diseases, malignancy or any other condition, that will influence treatment response, study adherence or survival in the judgement of the investigator, especially:

  1. Clinically significant evidence of severe or extra-thoracic TB (e.g., miliary TB, TB meningitis, excluding limited lymph node involvement)
  2. Serious lung conditions other than TB or significant respiratory impairment in the discretion of the investigator
  3. Peripheral neuropathy (as evaluated by the Brief Peripheral Neuropathy Score).
  4. Significant psychiatric disorder like depression or schizophrenia; especially if treatment for those has ever been required in the last five years or is anticipated to be required.
  5. An established diagnosis of diabetes mellitus.
  6. Cardiovascular disease, such as myocardial infarction, heart failure, coronary heartdisease, arrhythmia, tachyarrhythmia, or pulmonary hypertension.
  7. Current (as measured on two occasions during screening) or history of hypertension (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure of ≥90 mmHg) on two occasions. Controlled hypertension is permitted if the patients receive only the allowed anti-hypertensives.
  8. Long QT syndrome or family history of long QT syndrome or sudden death of unknown or cardiac-related cause.
  9. Alcohol or other drug abuse, that is sufficient to significantly compromise the safety or cooperation of the patient, includes substances prohibited by the protocol, or has led to significant organ damage, at the discretion of the investigator. An isolated positive test for cannabinoids does not fulfil this exclusion criterion.
  10. Chronic kidney disease (CKD) or any other history of renal impairment.

• Any of the following laboratory findings at screening:

  1. serum amino aspartate transferase (AST) and/or alanine aminotransferase (ALT) activity >3x the ULN
  2. serum alkaline phosphatase (ALP) >3x the ULN
  3. serum total bilirubin level >1.5 times the ULN
  4. estimated creatinine clearance (eCrCl) < 60 mls/min (calculated using the Cockcroft and Gault formula
  5. haemoglobin level <8.0 g/dL
  6. platelet count <50,000/mm3
  7. albumin < 2.8 g/dl
  8. serum potassium <3.5 mmol/L (not excluded if subsequently corrected)
  9. serum magnesium < 0.5mmol/L (not excluded if subsequently corrected)

• Any of the following ECG findings at screening:

  1. QTcF of > 450 milliseconds (ms)
  2. Atrioventricular (AV) block with PR interval > 200 ms
  3. QRS complex > 120 ms
  4. any other changes in the ECG that are clinically relevant as per discretion of the investigator

• Any of the following regarding concomitant medications at screening:

  1. Previous treatment with first- and second-line anti-TB drugs within the last 3 months prior to screening.
  2. Treatment with any other investigational drug (including vaccines) within 1 month prior to enrolment or enrolment into other clinical (interventional) trials during participation.
  3. Unable or unwilling to only take the allowed concomitant medications for this studyand ensuring an appropriate washout period
  4. Unable or unwilling to abide to the dietary restrictions required in this study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

90 participants in 4 patient groups

Arm 1

Active Comparator group

Description:

Drug: Moxifloxacin Moxifloxacin will be dosed at the licensed dose of 400 mg orally once daily for 16 weeks Drug: Bedaquiline Bedaquiline will be dosed at 400 mg orally once daily for the first 2 weeks, followed by 100 mg orally once daily for 14 weeks Drug: Delamanid Delamanid will be dosed at 300 mg orally once daily for 16 weeks

Treatment:

Drug: Moxifloxacin

Drug: Delamanid

Drug: Bedaquiline

Arm 2

Experimental group

Description:

Drug: Bedaquiline Bedaquiline will be dosed at 400 mg orally once daily for the first 2 weeks, followed by 100 mg orally once daily for 14 weeks Drug: Delamanid Delamanid will be dosed at 300 mg orally once daily for 16 weeks Drug: BTZ-043 BTZ-043 will be dosed at 500 mg orally once daily for 16 weeks

Treatment:

Drug: BTZ-043

Drug: Delamanid

Drug: Bedaquiline

Arm 3

Experimental group

Description:

Drug: Bedaquiline Bedaquiline will be dosed at 400 mg orally once daily for the first 2 weeks, followed by 100 mg orally once daily for 14 weeks Drug: Delamanid Delamanid will be dosed at 300 mg orally once daily for 16 weeks Drug: BTZ-043 BTZ-043 will be dosed at 1000 mg orally once daily for 16 weeks

Treatment:

Drug: BTZ-043

Drug: Delamanid

Drug: Bedaquiline

Arm 4

Experimental group

Description:

Drug: Bedaquiline Bedaquiline will be dosed at 400 mg orally once daily for the first 2 weeks, followed by 100 mg orally once daily for 14 weeks Drug: Delamanid Delamanid will be dosed at 300 mg orally once daily for 16 weeks Drug: BTZ-043 BTZ-043 will be dosed at 1500 mg orally once daily for 16 weeks

Treatment:

Drug: BTZ-043

Drug: Delamanid

Drug: Bedaquiline